Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

342,868 studies
in
216 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 08/05/2020.
Displaying: 746 trials in your specialties ()
View trials across your selected specialties

The Effect of Intra-Articular Injection of RegenoGel-OSP™ (Self-Plasma) and RegenoGel™ on Knee Pain in People Suffering From Osteoarthritis

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Osteoarthritis, Knee
View Full Trial
INTERVENTION

Device: RegenoGel-OSP, RegenoGel

Eligibility
  • Ages: 55 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Hadassah Medical Center, Jerusalem, Israel

Brief Summary

This study evaluates the efficacy of intra-articular administration of RegenoGel-OSP™ and RegenoGel™ to treat knee pain and effect on subject's activity and quality of life. During the study the subjects will receive two treatments at a 3-month interval. The study is double-blinded. The subjects will be randomized and sequentially assigned to RegenoGel-OSP™, RegenoGel or placebo treatment in the first treatment. In the second treatment after interval of three months all the subjects will necessarily receive one of the two active products. The follow-up period will continue for one year after first treatment.

Helicobacter Eradication Aspirin Trial

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Gastrointestinal Ulcer Haemorrhage, Bacterial Infection Due to He...
View Full Trial
INTERVENTION

Drug: Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg, Drug: Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg

Eligibility
  • Ages: 60 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Queen's University, Belfast, United Kingdom

Brief Summary

HEAT (Helicobacter Eradication Aspirin Trial) is a large simple double-blind placebo controlled outcomes study of Helicobacter pylori (H. pylori) eradication to prevent ulcer bleeding in aspirin users. It will be run by the University of Nottingham, with recruiting centres across the UK. This trial is funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme. Aspirin use is widespread and increasing in elderly patients. The main hazard is gastrointestinal bleeding, which may be increasing because of increasing aspirin use. This trial is based on evidence that peptic ulcer bleeding in aspirin users occurs predominantly in H. pylori positive people. Patients will be identified by their GPs, then asked to attend an appointment with a Research Nurse to consent to the trial and take a H. pylori breath test. Those with a positive result will be randomised to receive a one week course of either eradication treatment or placebo. No follow-up visits are required, but instead information will be extracted from the patients' electronic medical record using the MiQuest search tool. The trial will continue until 87 adjudicated events (hospitalisation because of definite or probable peptic ulcer bleeding) have occurred, which would occur after a mean 2.5 patient years of follow-up, if trial assumptions are correct.

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Polycystic Kidney, Autosomal Dominant
View Full Trial
INTERVENTION

Drug: Curcumin, Other: Placebo

Eligibility
  • Ages: 6 to 25 Years (Child, Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States

Brief Summary

The proposed research will determine the effectiveness of curcumin for improving the health and function of arteries in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). The study also will provide insight into how curcumin improves artery health by determining the physiological mechanisms (biological reasons) involved and offer exploratory evidence if curcumin can slow kidney growth. This will be done by comparing these measurements in children and young adults who are randomized to receive either curcumin or placebo for 1 year.

The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Heart Failure, Exercise Tolerance, Vasodilation, Body Composition...
View Full Trial
INTERVENTION

Drug: Neprilysin, Drug: Enalapril

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Marcelo Rodrigues dos Santos, São Paulo, SP, Brazil

Brief Summary

Studies with new drugs in the treatment of heart failure (HF), such as the combination of valsartan/sacubitril, also known as LCZ696, have demonstrated important clinical impact on the morbidity and mortality outcomes in HF population. However, the effect of LCZ696 on the pathophysiological mechanisms of HF such as exercise tolerance (peak VO2) and peripheral muscle blood flow is not known. Since LCZ696 is a new drug with promising effects on the treatment of HF, the objective of the present study will be to evaluate the effect of LCZ696 in patients with HF on: 1) peak VO2, 2) 6-minute walk test, 3) peripheral muscle blood flow, 4) muscle strength, and 5) body composition.

Short Term Results of Platelet-rich Plasma in the Treatment of Chronic Anal Fissure

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    PRP, Anal Fissure Chronic
View Full Trial
INTERVENTION

Biological: prp injection, Drug: Anrecta, Behavioral: sitz bath, Dietary Supplement: nutrition regulation

Eligibility
  • Ages: 18 to 65 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Karatay Medicana Üniversitesi, Konya, Turkey

Brief Summary

Autologous PRP currently has many uses in surgical and medical therapy. Compared with other regenerative therapies, PRP is easy-to-prepare, low-cost, and does not require complex equipment. The use of autologous PRP avoids immunological side effects. Data is lacking on the use of PRP in the treatment of anal fissure. This study evaluated PRP as an alternative medical treatment for chronic anal fissures.

Weight Loss With Risedronate for Bone Health

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Bariatric Surgery Candidate, Bone Loss, Weight Loss
View Full Trial
INTERVENTION

Drug: Risedronate Sodium 150 MG, Other: Placebo

Eligibility
  • Ages: 40 to 79 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Wake Forest University, Winston-Salem, North Carolina, United States

Brief Summary

This is a pilot project to determine the feasibility of recruiting, enrolling, treating, and following 24 older sleeve gastrectomy patients into a randomized controlled trial (RCT) examining the efficacy of bisphosphonate use versus placebo in the prevention of surgical weight loss associated loss of bone mass and quality.

Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Influenza, Human
View Full Trial
INTERVENTION

Biological: Inactivated influenza vaccine (NH formulation), Biological: Inactivated influenza vaccine (SH formulation), Biological: Placebo

Eligibility
  • Ages: 70 to 79 Years (Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

The University of Hong Kong, Hong Kong, China

Brief Summary

This study evaluates the immunogenicity of adding inactivated influenza vaccine with southern hemisphere (SH) formulation to standard once-annual influenza vaccination with northern hemisphere (NH) formulation in older adults in Hong Kong over 5 years. Half of participants will receive twice-annual influenza vaccination with NH and SH formulation, while the other half will receive once-annual influenza vaccination with NH formulation and a placebo.

Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Pulmonary Embolism and Thrombosis
View Full Trial
INTERVENTION

Device: Ekosonic® Endovascular Device ultrasonic infusion catheter, Biological: Recombinant tissue plasminogen activator

Eligibility
  • Ages: 18 to 75 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Cedars Sinai, Beverly Hills, California, United States

Brief Summary

The objective is to determine the optimum dose of thrombolytic and duration of the ultrasound procedure (together defined as the APT Procedure) as a treatment for acute submassive pulmonary embolism (PE). Symptomatic submassive PE are participants with acute (less than or equal to [≤]14 days) PE with normal systemic arterial blood pressure (greater than [>] 90 mmHg) and evidence of RV dysfunction (right ventricular to left ventricular diameter ratio, that is; RV/LV ratio greater than or equal to [≥] 0.9). Participants with submassive PE will be randomized to one of four APT treatment groups: ultrasound of 2 and 6 hours (hrs) with r-tPA 2 milligrams (mg)/hr/catheter and ultrasound 4 and 6 hours with r-tPA, 1 mg/hr/catheter. On 08 June 2016, randomization into treatment group 4 (APT/6 hours-r-tPA/2 mg/hr/catheter) was closed following a reported intracranial hemorrhage (ICH) and death in a study participant in this arm.

The Effect of Local Anesthetic and Clonidine on the Cutaneous Silent Period During Spinal Anesthesia

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Inguinal Hernia, Spinal Anesthesia
View Full Trial
INTERVENTION

Drug: levobupivacaine, Drug: clonidine

Eligibility
  • Ages: 18 to 60 Years (Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: Yes
Locations

Clinical Hospital Dubrava, Zagreb, Croatia

Brief Summary

The cutaneous silent period is a non-invasive technique that gives insight into the function of thin A delta fibers and as such can be a complement to conventional electrophysiological methods used to study the peripheral nerves. Clonidine is a selective partial agonist of the alpha-2 receptors which, added intrathecally to levobupivacaine, enhances the effect of a local anesthetic, prolongs sensory and motor block during local anesthesia and extends the length of post-operative analgesia. It is believed that clonidine achieves this effect by activating the postsynaptic alpha-2 receptors in the gelatine substance of the spinal cord and blocking the conduction of A-delta and C fibers. The aim of the study is to examine functional changes of Aδ - fibers during the application of spinal anesthesia by measuring the cutaneous slinet period and compare the effect of intrathecal administration of a combination of local anesthetic and clonidine in the quiet skin period in relation to the application of local anesthetic only.

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

  • Status
    Active, not recruiting
  • Phase
    Phase 4
  • Condition
    Varicella Zoster Vaccine
View Full Trial
INTERVENTION

Biological: VZV subunit vaccine

Eligibility
  • Ages: 50 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University Health Network, Toronto General Hospital, Multi-Organ Transplant, Toronto, Ontario, Canada

Brief Summary

The investigators plan to study the immunogenicity of the vaccine before and after lung transplantation. Patients (at least 50 years old) before and after lung transplantation will be enrolled. The investigators hypothesize that the recombinant varicella-zoster subunit vaccine is able to induce cellular immunogenicity after transplantation.